Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloid beta-Peptides | 5 | 2025 | 245 | 0.610 |
Why?
|
| Thrombocytopenia | 2 | 2005 | 204 | 0.390 |
Why?
|
| Memory, Episodic | 2 | 2023 | 57 | 0.370 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 630 | 0.280 |
Why?
|
| Pharmaceutical Services | 1 | 2008 | 76 | 0.260 |
Why?
|
| Valproic Acid | 1 | 2007 | 49 | 0.250 |
Why?
|
| Heparin | 2 | 2005 | 247 | 0.250 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2007 | 43 | 0.250 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 61 | 0.250 |
Why?
|
| Telomerase | 2 | 2010 | 246 | 0.240 |
Why?
|
| Education, Pharmacy | 1 | 2008 | 120 | 0.240 |
Why?
|
| Medical Records | 1 | 2007 | 192 | 0.240 |
Why?
|
| NAD | 2 | 2002 | 79 | 0.220 |
Why?
|
| Crystallins | 2 | 2002 | 61 | 0.220 |
Why?
|
| Temporal Lobe | 1 | 2025 | 107 | 0.210 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 61 | 0.210 |
Why?
|
| Thromboembolism | 1 | 2005 | 129 | 0.210 |
Why?
|
| Lens, Crystalline | 2 | 2002 | 136 | 0.200 |
Why?
|
| Frontal Lobe | 1 | 2025 | 160 | 0.200 |
Why?
|
| Glutathione | 2 | 2002 | 370 | 0.200 |
Why?
|
| Saliva | 1 | 2025 | 249 | 0.190 |
Why?
|
| Community Participation | 1 | 2024 | 123 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2005 | 748 | 0.190 |
Why?
|
| Ultraviolet Rays | 2 | 2002 | 385 | 0.190 |
Why?
|
| Memory Disorders | 1 | 2023 | 197 | 0.180 |
Why?
|
| Kynurenine | 1 | 2002 | 114 | 0.170 |
Why?
|
| Memory | 1 | 2023 | 297 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2024 | 321 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 630 | 0.160 |
Why?
|
| Pediatrics | 1 | 2008 | 1124 | 0.150 |
Why?
|
| Fibroblasts | 1 | 2004 | 1027 | 0.140 |
Why?
|
| Positron-Emission Tomography | 3 | 2025 | 343 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 468 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 1163 | 0.120 |
Why?
|
| Brain | 2 | 2025 | 2969 | 0.110 |
Why?
|
| Aniline Compounds | 2 | 2025 | 120 | 0.100 |
Why?
|
| Drug and Narcotic Control | 1 | 2012 | 24 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2012 | 69 | 0.090 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 67 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 208 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2002 | 532 | 0.080 |
Why?
|
| Humans | 15 | 2025 | 145750 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 106 | 0.070 |
Why?
|
| Overweight | 1 | 2012 | 614 | 0.070 |
Why?
|
| Phenytoin | 1 | 2007 | 21 | 0.060 |
Why?
|
| Phenobarbital | 1 | 2007 | 21 | 0.060 |
Why?
|
| Hyperammonemia | 1 | 2007 | 17 | 0.060 |
Why?
|
| Hallucinations | 1 | 2007 | 32 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 115 | 0.060 |
Why?
|
| Telomere | 1 | 2010 | 287 | 0.060 |
Why?
|
| Aged | 5 | 2025 | 26212 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 268 | 0.060 |
Why?
|
| Fructose | 1 | 2007 | 132 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 428 | 0.060 |
Why?
|
| Ethylene Glycols | 1 | 2025 | 17 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2025 | 20 | 0.060 |
Why?
|
| Pipecolic Acids | 1 | 2005 | 26 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2007 | 114 | 0.060 |
Why?
|
| Hirudins | 1 | 2005 | 53 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 534 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2007 | 246 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2007 | 867 | 0.050 |
Why?
|
| New Mexico | 1 | 2024 | 99 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 1044 | 0.050 |
Why?
|
| Clone Cells | 1 | 2004 | 263 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2010 | 877 | 0.050 |
Why?
|
| RNA | 1 | 2010 | 912 | 0.050 |
Why?
|
| Arginine | 1 | 2005 | 264 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 1102 | 0.050 |
Why?
|
| Antibodies | 1 | 2005 | 397 | 0.050 |
Why?
|
| Entorhinal Cortex | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 757 | 0.050 |
Why?
|
| Seizures | 1 | 2007 | 485 | 0.050 |
Why?
|
| Cell Death | 1 | 2004 | 382 | 0.050 |
Why?
|
| Orthopedic Procedures | 1 | 2005 | 244 | 0.050 |
Why?
|
| Acrylates | 1 | 2002 | 48 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 8346 | 0.050 |
Why?
|
| Benzoates | 1 | 2002 | 51 | 0.050 |
Why?
|
| Glucosides | 1 | 2002 | 56 | 0.040 |
Why?
|
| Benchmarking | 1 | 2023 | 191 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2004 | 226 | 0.040 |
Why?
|
| Middle Aged | 4 | 2025 | 36297 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1368 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1062 | 0.040 |
Why?
|
| Male | 6 | 2025 | 72992 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2025 | 696 | 0.040 |
Why?
|
| Cell Survival | 1 | 2004 | 1103 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2005 | 583 | 0.040 |
Why?
|
| Kinetics | 1 | 2004 | 1568 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 499 | 0.040 |
Why?
|
| Female | 6 | 2025 | 79025 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 892 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 184 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 1137 | 0.040 |
Why?
|
| Cattle | 1 | 2002 | 946 | 0.040 |
Why?
|
| Cell Line | 1 | 2004 | 2823 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1810 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2024 | 868 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2024 | 1782 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1482 | 0.030 |
Why?
|
| Hippocampus | 1 | 2022 | 973 | 0.030 |
Why?
|
| Cognition | 1 | 2023 | 1271 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 7133 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 4302 | 0.020 |
Why?
|
| Behind-the-Counter Drugs | 1 | 2012 | 1 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 24 | 0.020 |
Why?
|
| Laxatives | 1 | 2012 | 22 | 0.020 |
Why?
|
| Lactones | 1 | 2012 | 59 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 22569 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2007 | 11793 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2007 | 11866 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 40867 | 0.020 |
Why?
|
| Lung | 1 | 2004 | 4116 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 2010 | 8 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 72 | 0.020 |
Why?
|
| Retroviridae | 1 | 2010 | 100 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 132 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3915 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 247 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 322 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 335 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2007 | 17322 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 979 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 14250 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1184 | 0.020 |
Why?
|
| Child | 1 | 2007 | 22738 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1897 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1359 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2514 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 4151 | 0.010 |
Why?
|
| Animals | 1 | 2002 | 38100 | 0.010 |
Why?
|
| United States | 1 | 2012 | 16122 | 0.010 |
Why?
|